Erasca, Inc. (ERAS) Form 10-Q — Aug 11, 2026
Erasca reported a Q2 2026 net loss of $44.1 million ($0.14 per share), wider than the $33.9 million loss a year earlier, and a first-half net loss of $227.5 million that includes a $150.0 million in-process R&D charge for expanding its license territory with Joyo. The clinical-stage oncology company has no approved products or revenue and carries a $1.1 billion accumulated deficit. The balance sheet was substantially reinforced: a July 2026 underwritten offering sold 36,142,857 shares at $17.50 for $593.5 million in net proceeds, following a January 2026 offering that raised $242.7 million net at $10.00 per share.
Key figures
- Total Assets
- 435054000
- Cash Position
- 384300000
- Offering Price
- 17.5
- Shares Offered
- 36142857
- Shares Outstanding
- 349762035
- Cash runway
- at least twelve months including July 2026 offering proceeds
- H1 2026 eps
- -$0.74 vs -$0.23 in H1 2025
- Atm available
- $200.0 million remaining under ATM program as of June 30, 2026
- H1 2026 net loss
- $227.5 million vs $64.8 million in H1 2025
- Q2 2026 net loss
- $44.1 million vs $33.9 million in Q2 2025
- July 2026 offering
- 36,142,857 shares at $17.50; $593.5 million net proceeds after $38.9 million costs
- Q2 2026 ga expense
- $11.7 million vs $9.5 million in Q2 2025
- Q2 2026 rd expense
- $35.9 million vs $21.2 million in Q2 2025
- Accumulated deficit
- $1.1 billion
- Options outstanding
- 57,641,453 options with weighted-average exercise price of $4.29
- H1 2026 iprd expense
- $150.0 million related to Joyo license territory expansion
- January 2026 offering
- 25,875,000 shares at $10.00; $242.7 million net proceeds after $16.0 million costs
- Cash and equivalents only
- $42.5 million at June 30, 2026
- H1 2026 operating cash burn
- $54.7 million used in operating activities
- Total raised since inception
- $1.3 billion
Price after filing
Close on the filing date to close N calendar days later (from $18.41). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.